Market Closed -
Nasdaq
21:00:00 26/04/2024 BST
|
5-day change
|
1st Jan Change
|
14.89
USD
|
+1.43%
|
|
-1.59%
|
-11.42%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
386.4
|
346.2
|
698.1
|
1,936
|
1,792
|
1,757
|
-
|
-
|
Enterprise Value (EV)
1 |
291.9
|
205.9
|
506.8
|
1,637
|
1,655
|
1,296
|
1,071
|
1,757
|
P/E ratio
|
12.5
x
|
4.7
x
|
18.3
x
|
24.8
x
|
26.7
x
|
13.2
x
|
9.96
x
|
8.75
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.78
x
|
2.91
x
|
4.96
x
|
9.04
x
|
4.5
x
|
3.82
x
|
3.2
x
|
2.8
x
|
EV / Revenue
|
2.85
x
|
1.73
x
|
3.6
x
|
7.64
x
|
4.15
x
|
2.81
x
|
1.95
x
|
2.8
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
6.86
x
|
4.4
x
|
6.57
x
|
EV / FCF
|
8.44
x
|
4.57
x
|
8.54
x
|
14.1
x
|
11.5
x
|
7.67
x
|
4.89
x
|
7.17
x
|
FCF Yield
|
11.9%
|
21.9%
|
11.7%
|
7.09%
|
8.67%
|
13%
|
20.5%
|
13.9%
|
Price to Book
|
4.54
x
|
2.09
x
|
3.53
x
|
6.9
x
|
4.93
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
103,047
|
103,648
|
103,118
|
104,071
|
106,611
|
118,011
|
-
|
-
|
Reference price
2 |
3.750
|
3.340
|
6.770
|
18.60
|
16.81
|
14.89
|
14.89
|
14.89
|
Announcement Date
|
16/03/20
|
15/03/21
|
16/03/22
|
15/03/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
102.3
|
119.1
|
140.8
|
214.2
|
398.2
|
460.5
|
548.7
|
627.8
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
188.9
|
243.7
|
267.3
|
EBIT
1 |
31.82
|
41.3
|
52.38
|
101.8
|
86.81
|
179.1
|
240.5
|
284.5
|
Operating Margin
|
31.11%
|
34.69%
|
37.2%
|
47.54%
|
21.8%
|
38.89%
|
43.83%
|
45.31%
|
Earnings before Tax (EBT)
1 |
33.41
|
41.89
|
52.67
|
104.7
|
94.51
|
188.4
|
251.8
|
276.2
|
Net income
1 |
31.88
|
74.98
|
39.48
|
83.08
|
71.41
|
137
|
185.4
|
206.6
|
Net margin
|
31.16%
|
62.97%
|
28.03%
|
38.79%
|
17.93%
|
29.74%
|
33.8%
|
32.91%
|
EPS
2 |
0.3000
|
0.7100
|
0.3700
|
0.7500
|
0.6300
|
1.129
|
1.495
|
1.702
|
Free Cash Flow
1 |
34.59
|
45.02
|
59.35
|
116
|
143.4
|
169
|
219.2
|
245
|
FCF margin
|
33.81%
|
37.81%
|
42.14%
|
54.16%
|
36%
|
36.7%
|
39.96%
|
39.02%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
89.5%
|
89.97%
|
91.67%
|
FCF Conversion (Net income)
|
108.52%
|
60.04%
|
150.32%
|
139.65%
|
200.77%
|
123.42%
|
118.23%
|
118.57%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/03/20
|
15/03/21
|
16/03/22
|
15/03/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
35.95
|
38.31
|
43.09
|
53.11
|
57.24
|
60.76
|
85.37
|
99.58
|
102.7
|
110.6
|
98.77
|
112.1
|
120.9
|
128.7
|
125.2
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
49.83
|
60.81
|
56.12
|
54.42
|
-
|
EBIT
1 |
14
|
12.74
|
17.37
|
28.57
|
29.2
|
30.8
|
35.61
|
46.7
|
-37.19
|
41.69
|
32.6
|
44.47
|
49.59
|
52.45
|
47.57
|
Operating Margin
|
38.95%
|
33.26%
|
40.3%
|
53.79%
|
51.01%
|
50.7%
|
41.71%
|
46.9%
|
-36.21%
|
37.71%
|
33%
|
39.66%
|
41.02%
|
40.75%
|
37.99%
|
Earnings before Tax (EBT)
1 |
14.07
|
12.81
|
17.46
|
28.24
|
26.01
|
33.01
|
37.31
|
48.51
|
-38.02
|
46.71
|
37
|
46.68
|
51.18
|
53.56
|
49.91
|
Net income
1 |
10.33
|
9.309
|
13.24
|
21.62
|
22.75
|
25.47
|
29.57
|
37.76
|
-30.76
|
34.84
|
26.12
|
34.39
|
37.9
|
38.55
|
37.35
|
Net margin
|
28.73%
|
24.3%
|
30.73%
|
40.7%
|
39.74%
|
41.92%
|
34.64%
|
37.92%
|
-29.96%
|
31.51%
|
26.45%
|
30.67%
|
31.35%
|
29.95%
|
29.84%
|
EPS
2 |
0.1000
|
0.0900
|
0.1200
|
0.2000
|
0.2000
|
0.2200
|
0.2600
|
0.3300
|
-0.2900
|
0.2900
|
0.2121
|
0.2770
|
0.3078
|
0.3223
|
0.2833
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/11/21
|
16/03/22
|
10/05/22
|
09/08/22
|
09/11/22
|
15/03/23
|
10/05/23
|
09/08/23
|
08/11/23
|
28/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
94.5
|
140
|
191
|
298
|
138
|
461
|
686
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
34.6
|
45
|
59.4
|
116
|
143
|
169
|
219
|
245
|
ROE (net income / shareholders' equity)
|
36.4%
|
44.2%
|
19.1%
|
32.8%
|
20.7%
|
46.8%
|
24%
|
19.5%
|
ROA (Net income/ Total Assets)
|
28.4%
|
39%
|
16.6%
|
27.1%
|
16.9%
|
-
|
-
|
-
|
Assets
1 |
112.4
|
192.4
|
237.8
|
306.7
|
422.9
|
-
|
-
|
-
|
Book Value Per Share
|
0.8300
|
1.600
|
1.920
|
2.700
|
3.410
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
-
|
0.8700
|
1.340
|
-
|
Capex
1 |
0.02
|
0.01
|
1.02
|
0.03
|
0.23
|
0.06
|
0.16
|
0.17
|
Capex / Sales
|
0.02%
|
0.01%
|
0.72%
|
0.01%
|
0.06%
|
0.01%
|
0.03%
|
0.03%
|
Announcement Date
|
16/03/20
|
15/03/21
|
16/03/22
|
15/03/23
|
28/02/24
|
-
|
-
|
-
|
Last Close Price
14.89
USD Average target price
26.71
USD Spread / Average Target +79.41% Consensus |
1st Jan change
|
Capi.
|
---|
| -11.42% | 1.76B | | -4.66% | 86.13B | | +1.32% | 39.82B | | -19.27% | 30.42B | | +57.86% | 25.23B | | -16.09% | 15.35B | | -9.14% | 11.95B | | -17.69% | 11.6B | | -43.00% | 11.51B | | +5.24% | 8.71B |
Biopharmaceuticals
|